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You to all
members of the Medical Staff who
attended the information sessions
regarding the PHO. · Much useful
information was raised and important
suggestions were discussed.
Information will be distributed to the
Medical Staff regarding deliberations
and results of the PHO board meeting
which was held on Navember lS.
At the November 8 meeting of the
Hospital's Board of Trustees, Sam
Bub, M.D., was nominated to serve as
a trustee on the Hospital's Board.
Ratification of Dr. Bub to this seat will
occur at the Annual Board Meeting on
December 1.
Happy Thanksgiving to all!

Best regards,

h A. Candio, M.D.

.dent, Medical Staff

HAPPY
THANKSGIVING

John and Dorothy Morgan Cancer Center Opening
The John and Dorothy Morgan Cancer
Center will be open for patient care in
December, 1993. Upon openina, all
outpatient cancer chemotherapy and blood
components will be administered at the
John and Dorothy Morpn Cancer Center.
Additional procedures for cancer patients
which wnt be performed at the John and
Dorothy Morgan Cancer Center include
spinal taps, intrathecal administration of
chemotherapy, bone marrow aspiration,
bone marrow biopsy, thoracocentesis,
paracentesis, IV antibiotics, IV hydration,
and pain control blocks.. To schedule a
patient for any of these procedures, please
call 402-0539.
Some radiation therapy services will be

available at the Cancer Center sometime in
mid-December. One of the linear
accelerators will be available for patient
care. Two additional linear accelerators
are in the process of being installed and
wnt be available for patient care sometime
in January or February, 1994. The
telephone number for Radiation Therapy
Services at the John and Dorothy Morgan
Cancer Center is 402~00.
Until all radiation therapy services are
transferred to the John and Dorothy
Morgan Cancer Center, the radiation
therapy unit at 17th & Chew wlll continue
to care for patients. That telephone
number is 402-2283.
If there are any additional procedures or

services that you would like to have
performed at the John and Dorothy
Morgan Cancer Center, please contact
David Prqer, M.D., Director, John and
Dorothy Morgan Cancer Center, through
the Department of Medicine at 402-8200.
To mark the opening of the John and
Dorothy Morgan Cancer Center, a full
schedule of special events has been
planned as follows:

• Building Dedication - Monday,
November 29, 7 to 9 p.m.
This special, invitation-only event is
desiped to show appreciation to those
who were instrumeDtal in the development
of the Cancer Center, including the Board
of Trustees, medical aud hospital
leadership, donors, and coJDJDUnity
leaders. It will include the building
dedication, buffet-style dining and facility
tours. The program will feature remarks
by Pennsylvania's Acting Governor, The
Honorable MartS. Singel.
• Hospital Family Open House Tuesday, November 30, 6:30 to 8:30p.m.

Members of the Medical Staff, employees,
volunteers, auxllians, and associates are
invited to this festive party. They will
enjoy liJht refreshments and facility tours
as they learn about the services in the new
cancer center.
• Grand Opening - Wednesday,
December 1, 6:30 to 8:30 p.m.

A nbbon cutting, dedication of the Pave
the Way for Ufe Patio, and educational
activities will be the hi&hlights of this
major event, open to the general public.
There wlll be refreshments and tours of the
facility.
The Lehigh Valley Hospital Annual
Meeting will immediately precede the
Cancer Center Grand Opening on
Wednesday, December 1. The Annual
Meeting will begin at 4:30 p.m., in the
Auditorium at Cedar Crest & 1-78.
Traditionally, a reception follows the
annual meeting; however, this year all
participants will be invited to join the
Open House at the Cancer Center.
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Mobile Lithotripsy Service
On November 9, the Department of
Urology, in conjunction with Boyce
Lithotripsy Services, began offering
treatment of urinary tract stones using
Bxtracorporeal Shock Wave
Lithotripsy. This is a non-invasive
procedure that is based on the idea of
exerting high-energy pressure waves on
a kidney stone, which crumbles the
stone into sand-grain sized particles
and allows the patient to pass these
particles spontaneously.
The mobile unit will arrive at Cedar
Crest & 1-78 the evening prior to
service dates. It will be parked on a
cement pad located on the service road
adjacent to the Shockfl'rauma Unit.
This was formerly the location of the

Shockfi'rauma ttailer. Services will be
scheduled four days per month.
For patient safety and comfort, there
will be no smoking permitted in this
area. There is a oxygen and a halon
fire alarm system on the unit
This is an outpatient service which will
enable patients from the Lehigh Valley
to receive treatment in their own
community. Hospitalization is usually
not necessary.
If you have any questions regarding
this procedure, please contact Richard
M. Lieberman, M.D., Chief, Division
of Urology, at 770-9700.

Telemetry on Medical/Surgical Areas
A proposal to provide telemetry on
select medical/surgical areas has been
recently approved by the Special Care
Committee and endorsed by Senior
Management. The medical/surgical
units 4A, 4C, and 7B will have the
capability to accept four telemetry
patients on each unit with the
monitoring of those patients occurring
in the central station of PCCU (for 4A
and 4C) and SCU (for 7B). In
addition, 6C has already been
accepting chemotherapy patients
needing telemetry with the actual
monitoring of the patients occurring on

on Tuesday, November 9. After

piloting and working out operational
issues, 4A and 7B will follow on
Tuesday, November 30.
If you have any questions or need more
information, please contact Terry A.
Capuano, Administrator, Patient Care
Services, at 402-8250.

scu.

In order to transition this new system,
4C began accepting telemetry patients
who meet the medical/ surgical criteria
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Transitional Trau111Q, Unit
' i'l November 14, the Transitional
·: rauma Unit returned to its newly
renovated home on the fifth floor, A
wing, at Cedar Crest & 1-78.

If you have any questions, please
contact Lois Zellner, Director, Patient
Care Services, Transitional Trauma
Unit, at 402-8765.

Neonatal Hip Ultrasound Now Available
Over the past few months, members of
the Department of Radiology/
Diagnostic Medical Imaging have
accumulated extensive experience in
neonatal hip ultrasound. This
experi~ce has involved scanning many
normal and abnormal patients who
were referred to the Department by
pediatricians and orthopedic surgeons.

As a result of this experience, the

Department of Radiology/Diagnostic
Imaging now offers this service at 17th
&. Chew. To schedule an appointment,
please call 402-2450.
If you have any questions regarding
this service, please contact Lisa Exten,
Administrator, Diagnostic Imaging, at
402-8088.

Diabetes Education
Consults at 17th & Chew
Beginnina December 1, Diabetes
Education consults will be handled by
Debra McGeehin, R..N., M.S.N., and
Deborah Swavely, R..N., M.S.N.,
Diabetes Education Specialists, instead
of the Helwig Diabetes Center. The
Helwig Diabetes Center, however, will
continue to handle consults for
pediatric and obstetric patients.
If you have any questions regarding

this issue, please contact Debra
McGeehin, R..N., M.S.N., or Deborah
Swavely, R..N., M.S.N., at 402-8775.
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Laboratory Update
Interim "Pending" Test
Reports
Health Network Laboratories has
recently reviewed the options the
Laboratory Information System offers
related to notification of pencllD&
results. Currently, an interim pendiq
report is issued whenever new activity
occurs. Occasionally, this results in
the lab sending reports that only
contain tests for which no results are
complete and all tests listed are
pending.
In response to numerous
recommendations by physicians to
discontinue the practice of printing
peudiq test results, the
Laboratory/Physician Advisory
Committee made the decision to
discontinue this practice. In those rare
cases where it might be necessary to
know the status of a specific test,
several options exist to determine if a
specific test is pending and include
inquiry into the PHAMIS Lastword
System or calling the laboratory.
Effective October 2S, interim lab
reports will contain all new activity
related to completed test results only.
Interim reports will contain the
notation:
***Interim Report***: Test Results
Pending/Final Report to Follow
This decision should in no way
compromise patient care; however, and
it will eliminate little utilized reports
sent to offices and save the costs of
generating and reporting these results.

If you have any questions or concerns
about this issue, please contact David
G. Beckwith, Ph.D., Administrator and
Clinical Director, Health Network
Laboratories, at 402-SlSO or beeper
1627.

Change to Microbiology
Order Screens in
PHAMIS
In order to make them easier to
understand and use, Microbiology has
changed the microbioloiY order
screens in PHAMIS. A sample of the
screens is included on page 17 of this
newsletter for your information.
Please use the wording on these two
screens when writing orders to further
assist the nursing staff and unit clerks
know which tests to choose. If there
are any special organisms you are
looking for, please list them under the
spedal request section.

If you have any questions or
comments, please call Georgia G.
Colasante, Supervisor, Microbiology,
at 402-8190.

Addition to Antibiotic
Susceptibility Reports
Antibiotic susceptibility reports will
now contain a relative estimate of
acquisition cost per daily dosage.
The scale is derived using a single $ to
equal a daily dosage expense of $0-10.
Multiples of that unit for each
antibiotic follow the drug name on the
report and range from $ to $$$$$.
The dollar ranges are:
Continued on Page 6
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s - $0-10/per day

$$ - $11-30/per day
$$$ - $31-sJ/per day
$$$$ - $61-100/per day
$$$$$ - mote tbaD $100/per day

Although cost is only one variable in
the choice of an appropriate antibiotic
aaent, it is hoped this information will
assist you in making appropriate and
cost effective choices when selecting
antibiotics. If you have any questions,
please contact Barbara Leri, Pbann.D.,
at 402-8880.

Respiratory Virus
Surveillance Program
The Microbiology/Virology

Department is beginning its Respiratory
Virus Surveillance Program for the flu
season. The value of the surveillance
program is to alert the Medical Staff
and other physicians which viruses are
circulating within the community in
order to ensure appropriate
immunization of their patients and to
activate preventive measures to protect
those for whom respiratory viral
infections may be life threatening.
It has been predicted that this wit he
an early season and there have already
been three outbreaks reported in

Louisiana in which Influenza A-Beijing
was isolated. The vaccine this year
contains A-Beijing, A-Texas, and also

B-Panama.

Microbiology/Virology will supply
specimen collection kits consisting of a
sterile container with phosphate buffer
saline to gargle, a· tube of viral
transport media, case history form, and
a clinical laboratory requisition form.

To collect the specimen:
1) The apecimen lboald be collected within two
day• md 110 l8ter tb8ll tbne daya from the
011111t of nepintory or flu-lib II)'IDptoma.
2) GUJle with llteri1e aaliDe in the cnntainet.
3) Spit aliDe back iato oontainer.

..u.

4) Pour
throet wubiDa directly into the
tube of piDt fluid.

S) Libel CUbe with pltia's JUUIIe, c!Ue, ad
Icatioa.. llld place Oil wet ice.
6) Complete ViroloiY History form iacluded in
plastic pouch.
7) Complete the Clinical Laboratory
R.equiaitioa form for each patient'• specimen
for outside ICCOUD.tl. Specimeas from patients
seen in the Emetpacy Deputmeat will be
Oldend darouJh PHAMIS with tbe test code
JNiiL for 111 IDfluma AlB scree~~. or RVCU
for a complete :a.piratory Virus atudy.
(Outaide ICCOUDtl, pleue specify if just Ill
influma screea il WIDted.) The COlt of an
IDflueaza Screen il $80, and the c'* far a full
. respiratory virus workup il $1;

8) Specimeaa from tbe

BmerJt:

sbould be hand. delivered to M•.
wet ice. Specimeas from outside •
abould be refripratecl UDti1 courier pU..
sbould be tnasported Oil wet ice.

Once the specimen is received in the
laboratory, it will be tested for
Influenza A and B (and other viruses
requested). Positive results will be
telephoned. Final reports will be
issued as soon as the isolate ~ ·
identified or when the 5pe(;.
determined to be negative. , _
:.
for Influenza Screen, two week:t tm
complete respiratory virus culture.)
If you have any questions or need

collection kits for your office, please
contact Georgia Colasante, Supervisor,
Microbiology, at 402-8190.
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Library
News

In anticipation of the installation of the
Library's new computerized card
catalog, and the increased training and
data entry requilements at this time,
new requests for remote access to
MBDLINB have been temporarily put
on hold.
Recent acquisitions at Cedar Crest &
1-78 include:
• Taylor. FamDy Medicine. 4th ed.
Springer, 1993
• Travdl. Myofasdal PaiD &

Dysfunctious: 1be Trlger Point
Manual, Vol. 2: Lower Extremities.
Williams & Willdns, 1993

• Sleisenger. GastroJntestlnal
Dlseasa. Sth ed. Saunders, 1993
New additions to 17th &. Chew
include:
• Zambito. ImmuuolO&Y aud
Infed:lous Diseases of the Mouth,
Bead, and Neck. Mosby-Year Book,
1991
• Avery. NeouatolO&Y:

Patbophysioloay and Mauaaemeut of

the Newborn. 4th ed. Lippincott,
1994

• Lazarus. Acute Renal Fallure. 3rd
ed. Churchill Livingstone 1993

New Infection Control Policy Approved
The Infection Control Committee and

the Medical Executive Committee
recendy approved a new policy
regarding Protective Attire Durin&
Procedures. This policy describes
dress and prep requirements for certain

procedures performed on patients.
These procedures include a variety of
line insertions, as well as operativetype procedures performed at the
bedside.

A Day With a Doctor
Once again, Lehigh County Medical
Society is sponsoring A Day With a
Doctor during which members of the
community are invited to join a
physician during a typical work day.
This year, the event will occur on
Wednesday, December 8, and it is
expected to be even more successful
than last year.

The requirements of this policy are in
keeping with the requirements of
aseptic· practice and OSHA's
Bloodbome Pathogen Standard, i.e.
protective attire to avoid exposure to
bloodbome pathogens.

For your information, a copy of this
new policy may be found on pages 1821 of this newsletter.

In order to notify the nursing units and
procedure areas of the individuals
participating, Medical Staff members
are requested to contact Medical Staff
Services at 402-9850 prior to
December 3 of their intended
participation and the names of any
individuals who will be joining them.
Medical Staff Services will then notify
the appropriate areas.
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Legal Briefings

With almost two decades of risk
management experience and data in
hospitals, a number of concepts
underlining the management of risk for
physicians are now supportable through
an analysis of malpractice claims
experience nationally and a large
volume of anecdotal information. Of
these concepts, the significance of
effective communication as a claims
prevention tool emerges consistently at
the top of the list.
A Detroit physician analyzed tapes of
74 visits to seven doctors and found
that only 16 patients were allowed to
explain the problem fully. Doctors

interrupted 52 patients before they ever
completed their first statement The
patients had an average of about 18
seconds before they were cut off by the
doctor. No matter how good the
clinical care, patients place peat
importance on how the interaction

occurs.

One of the most common ways a
physician communicates with a patient
1S by the telephone. It is important to
orient office staff to the significance of
telephone conversations with patients.
The comments made by office staff to
patients and the manner in which the
comments are made may lay the
foundation for a negative relationship
between the physician and the patient.

The .~Ysician may be a very caring,

senSttive and compassionate person,
but if that attitude is not carried out
and conveyed by the representatives of
the physician, the patient and/or the
patient's family may react accordingly.
If the patient telephoning must be
placed on bold by the office staff, this
should be done only with the patient's
permission and an apology is helpful if
the patient was required to wait. All
staff, upon hiring, should be oriented
to the telephone etiquette of the
physician and of the office.
Liability cases have been filed because
of inappropriate triage in the doctor's
office. Both professional and nonprofessional staff should be carefully
oriented .~d monitored occasionally by
the phyStCWl as to the appropriateness
of triaging telephone calls from
patients and families. An office policy
identifying the issues related to
telephone communication may be ·
helpful in providing consistency from
one staff person to another. Such a
policy may include issues related to
triaging, communication, and
documentation of telephone calls as
well as issues related to the manner of
communication expected by the
physician.
If you have any questions regarding
this or other legal issues, please
contact the Department of Legal
Services/Risk Management at
402-8201.
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Nutrition Label Countdown

by Elinbeth Martin, lt.D.

Clinical
Nutrition

News

New nutrition labeJiq will be mandatory by May 1994. Of particular interest to
health professionals are the teplations concerning food label health claims. Since
it is established that diet is one of a number of factors that may lower the risk of
certain diseasm, seven food-health relationships have been approved: sodium and
hypertalsion; fat and cancer; fruits, vegetables and pain products that contain
fiber and coronary heart disease; saturated fat and cholesterol and coronary heart
disease; fruits and vegetables and cancer; fiber containing pain products, fruit,
vegetables and cancer; calcium and osteoporosis.

Food processors may use the health claims if the product meets all three of the
following guidelines:
1. Maximum nutrient levels per standardized serving:
Food Product

Total fat

Saturated fat

Cholesterol
Sodium

13 g
4g
60mg
480mg

Maig Dish

Product Meal Product

19.5 g
6g
90mg
720mg

26g
8g
120 mg
960mg

2. Specific nutrient requirements for each of the IeVen health claims, i.e.: calcium
and osteoporosis health claim - food must have •hiah• (20~ or more of Daily
Value) level of calcium. Calcium must be assimilable and phosphorus levels may
not be higher than the calcium.
3. Food must contain at least 10~ of the Daily Value of one or more of these
nutrient: protein, dietary fiber, vitamin A, vitamin C, calcium or iron, i.e., fruits
and vegetables and cancer health claim food must be •good• (10 to 19~ of the
Daily Value) source of dietary fiber vitamin A and vitamin C.
These health claims may help consumers make better food selections.

For more information regarding nutrition labeling, contact Clinical Nutrition at
402-2200 (17th & Chew) or 402-8313 (Cedar Crest & 1-78).
References: Food Labelln&, Dr. I. Lynn Brown, 1993; Food Label Series,
National Food Processors Association, 1993.
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News from Research
A call for abstracts has been issued by

a number of organizations as follows:
• The American Society for Plastic
and Rec:onstructive Surgery for the
63rd Annual Meeting to be held on
September 24, 1994 in San Diego,
Calif. Submission due date is
February 15, 1994.

• The American Diabetes Association
for the 54th Scientific Sessions to be
held on June 11, 1994 in New Orleans,
La. Submission due date is January 7,
1994.

• The Society for Academic
Emergency Medicine for the 1994
Annual Meeting to be held on May 9,
1994 in Washington, D.C. Submission
due date is January 14, 1994.
• The Society for Clinical Trials for
the 15th Annual Meeting to be held on

May 8, 1994 in Houston, Texas.
·
Submission due date is December 17,

1993.

For instructions, forms, and further
information, please contact Kathleen
Moser in the Research Department at
402-8889.

Congratulations!
Alan B. Leahey, M.D.,
ophthalmologist, was recently informed
that he successfully passed the Oral
Examination of the Board Certification
Process and is now a Diplomate of the

American Board of Ophthalmology.

Brian W. Little, M.D., Ph.D.,
Director of Education, was recently
appointed to membership of the
Subcommittee on Continuing Medical
Education of the Pennsylvania Medical
Society for the 1993-94 term.

David M. Stein, D.O., general
internist, was recently approved for
certification in Internal Medicine by
the American Osteopathic Board of
Internal Medicine.

Marijo A. Zelinka, M.D.,
neonatologist, was recently informed
by the American Board of Pediatrics
that she successfully completed the
1993 Certifying Examination in
Neonatal-Perinatal Medicine.

William M. Markson, M.D.,
cardiologist, and his wife, Jane,
welcomed a baby daughter on October
15. Elizabeth Grace weighed 6 lbs., 5
oz., and was 20 inches long. She was
welcomed home by her brother and
sister, Jonathan and Rebecca.
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Publications, Papers and Presentations
Henry H. Fetterman, M.D.,
gynecologist, was a guest speaker at
the District ill Annual Meeting of the
American College of Obstetricians and
Gynecologists and the New Jersey
Obstetrical and Gynecological Society
held in Atlantic City, N.J., September
2~29. Dr. Fetterman's topic was
Cesarean Section and Utiptlon:
The Pennsylvania Experience.
Herbert L Hyman, M.D.,
gastroenterologist, was a recent guest
speaker at the VA Medical Center,
Wilkes-Barre, Pa., where he presented
Irritable Bowel Update with Bi•
Psycho Soclal Approach.
Peter A. Kebllsh, M.D., chief,
Di~monofonho~cS~my,was

an in~ted lecturer for the Second
International Course of the C.I.P.,
which was held at the Rizzoli Institute,
Bologna, Italy, from October ~10.
His lecture topic was Moveable

Bearlna Anlde Prosthesis.

In addition, Dr. Keblish presented a
scientific paper at the Pennsylvania
Orthopaedic Society 1993 Fall Meeting
in Philadelphia on November 4. The
paper is titled Abnormal PCL
JCinematlcs in TKA: Tibial Platform
Selection.
lndna T. Khubchandani, M.D.,

colon-rectal surgeon, moderated a
panel on inflammatory bowel disease at
the Tripartite meeting in Sydney,
Australia, on October 19. The
International Meeting was jointly held
by the Australian Society of
Coloproctology/Royal College of

Surgeons, British Association of
Coloproctology/Royal Society of
Medicine, and the American Society of
Colon and Rectal Surgeons.
Approximately 300 registrants,
including several renowned in~ted
speakers, participated.
. Dr. Khubchandani later mte vimted
Singapore, where he will be the
Program Chairman for the 15th
Biennial Congress of International
Society of University Colon and Rectal
S~eons to be held from July 2-4,
1994.
Alan B. Leahey, M.D.,
ophthalmologist, authored a paper titled
Suture Abscf&ws After Penetrating
Keratoplasty which was published in
the journal, CDnalltl, Volume 12,
Number 6, 1993. The article deals
with the risks of lea~g sutures in
corneal transplant wounds for long
periods of time. It also deals with
corneal ulcers and the coexistent graft
rejection and how to manage these
patients.

Thomas D. Meade, M.D., orthopedic
~eon, and the Allentown Sports
Medicine Center have been selected as
the outpatient sports medicine rotation
for the Sacred Heart Family Practice

Program.

Dr. Meade was also an in~ted lecturer
at the Lunch & Learn Proanun at
PP&L Nuclear Di~sion where he
presented Fmployee Fitness.
Continued on Page 12
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Larry N. Merkle, M.D., chief of the
Division of Endocrinology/Metabolism,

co-authored an article, F1alble Jmnlln
lalusloD Protocol for Use Ia Crltlc:al
Care, which was published in the
October, 1993 issue of PeiUI8JlwlnitJ

Mlllldlu.
Alexander D. Rae-Grant, M.D.,
neurologist, co-authored an article,
Type m lntermlttency: A NoDiinear
Dyaamlc Model of EEG Burst
Suppression, which was accepted for
publication in BUt:tmellcqhalo61'11PhY
tuUl Clbdctll NeurophyliDlof1.
Bruce L Rose, M.D., reproductive
endocrinologist, authored a DWluscript,
Sperm Motility, MorphoJou,
Byperacdvatlon and Ionophore
Induced Acrosome Reactloas After
OvemJabt Incubation with
Mycoplasma Spec:ies, which bas been
accepted for publication in Feltllit]
tuUl Sterlllty.
I .ester Rosen, M.D., colon-rectal
SUIJeoD and Program~ of the
ColoniRedal Residency Program, was
invited to present Are Simple Allal
F1stuJa Simple! at the 79th Annual
Clinical Congress of the American
College of Surgeons in San Francisco,

Calif. A study of 461 cases of
•simple• anal fistula treated by the
Division of Colon/Rectal Surgery
between 198S and 1991 was presented.
A favorable outcome (no recurrenc:e of
fistula) was obtained in 94 ~ of the
cues reviewed. An article on this
study bas been accepted for
publication in 1Jlutue1 of t1u Colon &
Rectllla.
In addition, Dr. Rosen was invited by
Dr. :Bernard Fisher, Chairman of the
National Surgical Adjuvant Bleast and
Bowel Project (NSABP) to present
Issues In Laparoscopk Slll"'ery for
ColoD/Rectal Cancer to the NSABP
session in Chica&o on October 31.
The presentation was based on the
philosophy tbat all these cases should
be on standardized protocols with
careful evaluation. Dr. Fisher asked
Dr. Rosen to serve as liaison to the
American Society of Colon and Rectal
Surgeons in initiating the new NSABP
protocols for rectal cancer.
Boward S. Selden, D.D.S.,
endodontist, authored a paper titled
PatleDt Empowerment - A Strate&Y
for Pain Control in Endodontics
which appeared in the October, 1993
issue of Joul"'llll of Blulo4ollllu.

Upcoming Seminars, Conferences, and Meetings
Medical Grand Rounds
Mip'alnes will be presented by Nathan

Blank, M.D., Associate Professor of
Neurology and Pathology; Program
Director, Neurology Residency; and

Chief, Division of Clinical Neurology,
The Medical College of Pennsylvania,
Philadelphia, Pa., on Tuesday,

November 23.

)

Continued on Peg• 13
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M.edleatloa Error will be presented by

Michael Cohea, R.Ph., F.A.S.H.P.,
Hospital Central Services, Allentown,
Pa., on Tuesday, November 30.
Medical Grand Rounds are held at
Noon in the Auditorium of Lehigh
Valley Hospital, Cedar Clat lc. 1-78.
For 1110te information, contact the
Department of Medicine at 402-8200.

18, from Noon to 1 p.m., in the
Auditorium of Lehigh Valley Hospital,
17th lc. Chew.
As lunch will be provided, preregistration is required. For more
information or to register, please
contact Lisa in the Department of
Psychiatry at 402-2810.

Department of Pediatrics

Regional Symposium
Series V

Common Urolo&ical. Problems In
Pediatrk:s will be presented by
Richard E. Caesar, M.D., Section of
Urology, St. Christopher's Hospital for
Children, Philadelphia, on Friday,
December 3.

Update OD Upper EUremlty aDd
Cenlc:al Splae Problems: A Primary
Care Approadl will be held on
Saturday, December 4, from 7:30a.m.
to 1 p.m., in the Auditorium of Lehigh
Valley Hospital, Cedar Crest & 1-78.

Commoa Problems In Pediatric
RadloiOIY will be presented by Eric
Faerber, M.D., Director, Department
of Radiology, St. Christopher's
Hospital for Children, on Friday,
December 17.

Orthopedic surgeons, general
practitioners, physicians' assistants,
physical therapists, nurses, and other
health professionals interested in an
update on upper extremity and cervical
spine problems will benefit from this
program.

The above programs will be held in the
Auditorium of Lehigh Valley Hospital,

17th lc. Chew, beginning at Noon. For
more information, contact Beverly
Humphrey in the Department of
Pediatrics at 402-2410.

Psychiatric Grand
Rounds
Post-Partum Psyclliatrie Disorders
will be presented by Bryce Templeton,
M.D., Vice Chairman and Director of
Psychiatric Residency Training
Program at Hahnemann University,
Philadelphia, on Thursday, November

At the completion of the program,
participants should be able to describe
the symptoms, diagnosis and treatment
of shoulder, elbow, hand, and cervical
spine problems in the general
population.

For more information regarding this
program, please call Human Resource
Development at 402-4609.
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• For Sale or Leaae - Springhouse
Profusional Center, 1575 Pond Road.
Ideal for physician' a office.
Approximately 2,500 sq. ft. Will
finiah apace to specification&.

• For Leaae - Medical office space
located in Peachtree Office Plaza in
WhitehaU. One suite with 1 ,500 sq.
ft. (unfinished - allowance available),
and one 1 ,000 sq. ft. finished suite.

• For Sale or Leaae - Medicalprofeaional office building on South
Cedar Crest Boulevard, just minutes
from Cedar Crest & 1-78 and 17th ll
Chew. 3,560 total sq. ft. Ample
parking, aecurity/fire alarms installed.
Ideal for physician group.

• For Leaae - Meclcal office space to
aublet In MOB 1 at Lehigh Valley
Hospital, Cedar Crest lll-78.

• For Sales or Lease - Medical/
Professional three-story office building
at 1730 Chew Street, Allentown.
Excellent condition with recent
renovations. Approximately 6,800
aq. ft~ for lingle or multiple specialty
practice. Includes long-term parking
lease at Fairgrounds. Potential
telephone and dictationa systems.
• For Sale - Office building at
Northeast corner of 19th and Turner
Streets in Allentown. Upper level 2,400+ sq. ft., large waiting room,
two large consultation rooms, five
exam rooms, etc. Lower level 2,300 + sq. ft. Parking lot for 16
cars.
• For Leaae- Office apace In 401 N.
17th Street to sublet. Approximately
1 ,500 sq. ft. with three exam rooms.
• For Lease - Medical-professional
office space located on Route 222 In
Wescosville. Two 1 ,000 sq. ft.
offices available or combine to form
larger suite.
• For Lease - Large, newly
remodeled, completely furnished
medical office apace available for
subleasing/time ahara at Cedar Crest
Professional Park. Top of the line
telephone system. Transcription and
computer system with electronic
billing available.

• For Leaae - Medical office apace
located in Southeast Allentown near
MountainviUe Shopping Center.
• For Lease - Slota are currently
available for the Brown Bag suite at
Kutztown Professional Center.
• For Lease - Share large medical
office near Cedar Crest & 1-78. Fully
furnished and staffed. Multiple Dna
phone system. Computerized bOling
available.
• For Leaae - Specialty practice timeshare apace available in a
comprehensive health care facility.
Riverside Professional Center, 4019
Wynnewood Drive, Laurys Station.
Half- or full-day slots Immediately
available.
• For Leaae - Professional office
apace available In an established
psychology and psychotherapy
practice at 45 North 13th Street,
Allentown. Large, warm VIctorian
building In a relaxed atmosphere.
Secretary and billing available and
included In some leaaea. Furnished or
unfurnished fuU offices and sublets
available. Utilities included.
For more information or for assistance
in finclng appropriate office apace to
meet your needs, contact Joe Pilla,
Physician Relations Rep, at 402-9856.
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WHO'S NEW
1be Who's New section of Mllliclll

SIII/I Progr~a Not•• contains an
update of new appointments, address
changes, newly approved privileges,
etc.

Please remember that each department
or .unit is responsible for updating its
directory, rolodexes, and approved

privilege rosters.

Medical StatT
Appointments
John G. Brady, DO
(Stephen M. Purcell, DO)

2200 Hamilton Street

Suite 106

Allentown, PA 18104
(21S) 770-1922
Department of Medicine
Division of Dermatology
Provisional Consulting
David Lezinsky, DO
(0naory J.ua, MD)

440 S. 15th Street
Allentown, PA 18102
(215) 437-7000
Department of Obstetrics and
Gynecology
Division of Obstetrics/Gynecology
Section of Benign Gynecology
Provisional Courtesy
Daniel E. Muser, MD

Carmine J. Pellosie, DO

Affinity
1243 S. Cedar Crest Blvd.
Allentown, PA 18103
(215) 402-9292
Department of Medicine
Division of Occupational Medicine
Provisional Courtesy

Address Changes
Matthew A. Kasprenski, MD
(formerly Employee Health)

1574 Duxbury Court
Allentown, PA 18104-1943
(215) 395-6445
Please note that the above doctor's son,
Matthew L. Kaspreusld, M.D., is
also a member of the Medical Staff.
His address is 2416 Third Street,
Whitehall, PA 18052, and remains
unchanged.

Crai& R. Reckard, MD

1210 S. Cedar Crest Blvd.

Suite 2800

Allentown, PA

18103

lbomas E. Young, MD
(Sam Bub, MD, PC)

619 Dalton Street
Emmaus, PA 18049
(215) 967-3646

Practice Name Change
From Pascuzzo and Shah
to Shah and Giangiulio

(David B. Yaootf, MD, PC)

246 N. 6th Street

Lehighton, PA 18235
(215) 377-2224
Department of Surgery

Continued on Page 18

Di~sionof~~cSurgmy

Provisional Consulting

Page 15

Continued from Page 15

Change of Status
Fred H. Roland, MD
Department of Medicine
Division of Family Practice
From Courtesy to Emeritus Courtesy

Additional Privileges
Bryan W. Kluck, DO
Department of Medicine
Division of Cardiology
Transluminal Atherectomy Extraction

Allied Health
Professionals
Appointment

GaD K. Neff, GN
Physician Extender
Professional - GN
(Valley Sport. a: Artluitia Suraeona • David

Su-nan, MD)

Resignation

James E. Sloma, DO

(But Pean Family Practice)

Department of Medicine
Division of Family Practice
Provisional Referring
)

)
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- - - - - tiiCROBIOLOGY ORDER SCREEN
J

l

New II: Oo

Order: -----------------------------Frequency: _ __
Priority: _
Source:
Ord MD: ----------------~nt:

Special Request: --------------------Collected By: _
COLLECT DIT: - - -

END:---

Status:
DC/Hold:
udit Trail (Y):
'iTERED:
iANGED:

Dept:
Ord Loc:
Pt Ord II:
User:
User:

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I

210ct93 11:34am JW 2.7 ORDDMICR CC·
,
MICROBIOLOGY ORDERS,
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

Blood Culture
Blood for CMV Cult.
Blood Cult. Fungus
Blood Cult. TB/MAI
Bronch Specimen C&S
Includes Gram Stain
C difficile
catheter Tip c&s
Chlamydia DFA
CSF ORDER SET
Fungus Cult./Routine
GC Screen only
Genital c & s
Genital GpB Str only
Ova & Parasites

'BA

for CMV Cult.
:nood Culture
3lood Cult. Fungus
3lood Cult. TB/MAI
3ordatella Culture
3ronch Specimen C&S
tncludes Gram Stain
lurn Wound Culture
:atheter Tip C&S
:hlalll)'dia Culture
:hlamydia DFA
: diffici le
~lood

13. CHV Culture
Non-blood specimens
14. CAPO Fluid C & S
Has Gm Stain & Anaerobic C&S
15. CSF ORDER SET
16. Fungus Cult./Routine
17. Fungus hair/nail/skn
18. Gastric Culture
Includes Gram Stain
19. Giardia Ag Screen
20. GC Screen only
21. Genital C & S
22. Genital GpB Str only

PMLW

15. Spinal Fluid C & s
Includes Gram Stain
16. Sputum/Trach C & S
Includes Gram Stain
17. Stool Culture
18. TB/MAI/AFB Culture
19. Throat Cult GP A Str
20. Urine C & S
NO Gram Stain Included
21. Wound or Fluid C &S
Includes Gram Stain
22. Anaerobic Culture
Has Gm Stain & Aerobic c&s

Use <MENU> for more Micro studies
Select II:

- - - - -

190ct93 9:20am JW · 1.1 tiNMICRAA CC
MI C R 0 B I 0 L 0 G Y

IJ1025

0 R DE R

W2227

PtiLW

ME N U

23. Herpes Simp. Virus C
24. Influenza A/B Screen
Ages 13 to Adult
25. Legionella Culture
Not urine ·
26. Ova & Parasites'
27. Pneumocystis DFA(PCP
28. RSV DFA
29. Spinal Fluid C & S
Includes Gram Stain
30. Sputum/Trach C & S
Includes Gram Stain
31. Stool Culture
32. Stool for WBC's

33. TB/MAI!AFB Culture
34. Throat Cult GP A Str
35. Urine c & s
NO Gram Stain Included
36. Virus Nonrespiratory
37. Virus Respiratory
38. Woun~ Fld. - Aerobic
Includes Gram Stain
39. Wound Fld. - Anaerob
Has Gm Stain & Aerobic C&S
40. Blood Parasites
41. Gram Stain
42. India Ink
43. KOH Preparation

Select Order(s):
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POLICY NO:

SUBJECT:

IC

Protective Attire During
Procedures

EFFECTIVE DATE:
AREAS AFFECTED:
PAGE:
I.

1 of 4

POLICY

To provide a safe environment for natients and staff, standards of 1r ··.ss
must be followed when procedures . we performed (outside of an Oper
;;
Room Suite).
II.

SCOPI

All personnel.
III.

DlriNITIOIS
Category

A ~ee - Insertions of PEG Tubes (Bedside or GI Lab)
Insertion of Peritoneal Dialysis Catheters
Insertion of IABP via Cutdown
Tracheostomy (Bedside)
Bronchoscopy (Bedside)
Any Procedure Normally Performed in the OR
Insertion
Inse1 t j Nl
Insert .. an
Insertion
Insertion
Insertion
Insertion
Insertion
Device

of
of
of
of
of
of
of
of

SG Catheter
all Centrally Placed Venous Catheters
Guidewires
Arterial Lines
Cutdowns
Percutaneous IABP
Chest Tubes
Intracranial Pressure Monitoring

Category C Procedm ee - Lumbar Puncture

Insertion of Urinary Catheter (straight or
indwell inp;)

Category D Procedures - Venipuncture

Insertion of Peripheral IV
Any Direct Manipulation of Tubing to Central or
Arterial Catheter Junction or Stopcocks
(i.e. tubing change, collection of blood
specimens) .

)
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POLICY:

IV.

IC

PAGE: 2 of 4

PHOCIDUBI

ActiOD

A.

B.

Respaasibility

Category A Procedures
1.

Don face protection (mask with eyewear or
mask with face shield).

Physician
Medical Student
Assistants in
Immediate Vicinity

2.

Don hair cover.

Physician
Medical Student
Assistants in
Immediate Vicinity

3.

Perform surgical scrub.

Physician
Medical Student

a.

Assistants

Wash hands with antiseptic soap.

4.

Don sterile gown and sterile gloves.

Physician
Medical Student

5.

Use sterile drapes to maintain sterile
field.

Physician
Medical Student

Category B Procedures
1.

Don face protection (mask with eyewear or
mask with face shield).

Physician
Medical Student
Assistants in
Immediate Vicinity

2.

Don hair cover.

Physician
Medical Student
Assistants in
Immediate Vicinity

3.

Wash hands with antiseptic soap.

Physician
Medical Student
Assistants in
Immediate Vicinity

4.

Don gown and sterile gloves.

Physician
Medical Student

a.

5.

Don sterile gown and sterile gloves
for all Category B Procedures performed on patients in STU or BU.

Use sterile drapes to maintain sterile
field.

. Physician
Medical Student
Physician
Medical Student
Page 19

POLICY:

IC

ActiOD
C.

D.

Bespoll!ibility

Category C Procedures

1.

Don face protection (mask with eyewear or
face shield) if increased pressure is
suspected.

All Personnel

2.

Wash hands with antiseptic soap.

All Personnel

3.

Don sterile gloves.

A11 Personne 1

4.

Use sterile drapes to m.aintain sterile
field.

All Personnel

Category D Procedures

1.

Wash

2.

Don clean gloves.

All Personne 1

3.

Use antiseptic swab to prepare insertion
site or to disinfect catheter/tubing junction.

All Personnel

a.

V.

PAGE: 3 of 4

~ands

with antiseptic soap.

All Personnel

Allow for at least 30 seconds of
contact time before initiating procedure.

Aft~

None
VI.

DISTRIBU!IOR

Infection Control Manual
VII.

APPROVAL

Signature

VIII.

Chairman
Infection Control Committee

Date:

July 26, 1993
Infection Control Committee Approval

Date:

September 7, .1993
Medical Executive Committee Approval

Date

)

POLICY IISPORBIBILITY
Infection Control Department
IN OOORDIRA'l'IOif WI'l'B:
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POLICY:

PAGE: 4 of 4

IC

Precautions Necessary with Central Venous Catheters.
July, 1989, Volume 19, Number 2.

FDA Bulletin.

Bloodborne Pathogen Standard. Occupational Safety and Health
Administration. March 1992.
X.

BIVISIOIS

Hospital reserves the right unilaterally to revise, modify, review,
rescind or alter the terms and conditions of this policy within the
constraints of the law, by giving reasonable notice.
XI.

otBI8S

N/A
XII.

DA'I'IS

Origination:

7/84

Last Review:

7/93

Next Review:

7/95

)
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.EHit;HVAILEY
HOSPITAL

P & T Highlights
The following action were
taken at the October 13, 1993
Pharmacy and Therapeutics
Committee Meeting
James A. Giardina,
Director of Pharmacy

FORMULARY.!WDITION REQUEST
"Primacor or Inocor"
Milri.none lactate (PrimacorR, Sanofi-Wmthrop)-

is a more potent derivative of amrinone indicated
for the short-term therapy of CHF. Like
amrinone, milrinone has also been used in the
treatment of low cardiac output following cardiac
surgery. Milrinone exhibits inotropic and
vasodilatory effects by blocking phosphodiesterase
in cardiac and vascular muscle. This results in
improvement in cardiac output, pulmonary
capillary wedge pressure, and peripheral vascular
resistance. Milrinone is primarily excreted
unchanged in the urine (83%) and because of this,
patients with severe renal failure will have an
extended half life from 2.3 hr to 3.24 hr and may
require lower infusion rates. The most colnmon
adverse reactions are ventricular arrhythmias,
hypotension and headache. Less common side
effects include angina, hypokalemia, tremor,
fever, bronchospasm and thrombocytopenia.
Milrinone's reported risk of thrombocytopenia is
less than that of amrinone, 0.4% compared to
2.4%, respectively. Milrinone is physically
incompatible with furosemide (Lasix), therefore

furosemide injection should not be given through
an IV line containing milrinone. Milrinone is
compatible with Dextrose (unlike amrinone).
Cardiac function, renal function, fluid status and
electrolytes, especially potassium, should be
monitored. Dosage adjustments should be made
on the basis of cardiac function studies.
Milrinone is given as a loading dose of 50mcg/Kg
infused slowly over 10 minutes followed by a
maintenance infusion of 0.375 to
0. 75mcg/Kg/min. Table 1 shows delivery rates
in ml/Kg/hr for various concentrations and
infusion rates. Table 2 shows dosage adjustments
for decreasing creatinine clearances. Milrinone
appears to offer advantages over amrinone in its
side effect profile (thrombocytopenia) and cost
$144-384/day (Milrinone) vs $263-482/day
(Amrinone). Milrinone was added for a 6 month
therapeutic evaluation with the intent of stocking
only one agent at the conclusion of the trial.

)
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TABLE 1: Delivery Rates in Normal Renal Function
Milrinone Rates of Infusion

Milrinone Infusion Rate in Impaired Renal Function

Infusion Delivery Rate'
Milrinone
(meg/kg/min)

100mcg/ml2
(mllkg/hr)

150mcg/ml 3
(mllkg/hr)

TABLE 2: Infusion Rates in Renal Impairment

200mcg/ml(
(ml/kg/hr)

0.375

0.22

0.15

O.ll

0.4

0.24

0.16

0.12

0.5

0.3

0.2

0.15

0.6

0.36

0.24

0.18

0.7

0.42

0.28

0.21

0.75

0.45

0.3

0.22

Creatinine clearance
(ml/min/1. 73 m2)

Infusion rate
(meg/kg/min)

5

0.2

10

0.23

20

0.28

30

0.33

40

0.38

50

0.43

In order to calculate flow rate (ml/hr), multiply infusion delivery
rate times patient weight (in kg).
2 Prepare by adding 180ml diluent per 20mg vial (20ml).
3 Prepare by adding ll3ml diluent per 20mg vial (20ml).'
4 Prepare by adding 80ml diluent per 20mg vial (20ml).
Diluents which may be used to prepare. dilutions of milrinone for IV
infusion are 0.45 % or 0. 9% Sodium Chloride Injection, USP or
5% Dextrose Injection, USP.

Cisapri.de (Propulsifll, Janssen) - is a prokinetic
agent structurally and pharmacologically
?issimilar to metoclopramide. Like
lnetoclopramide, it is indicated for the
symptomatic treatment of patients with nocturnal
heartburn due to GERD. Cisapride works as an
indirect cholinergic agent on the GI tract. Unlike
metoclopramide, cisapride has no effect on
dopaminergic receptors. Cisapride is rapidly
absorbed following oral administration with an
absolute bioavailability of 35-40%. It has a halflife of 6-12 hours and is extensively metabolized
prior to elimination. Cisapride exhibits some
accumulation in hepatic or renal impaired patients
as well as elderly patients, as compared to young
healthy volunteers, but the differences are
inconsistent and dosage adjustment is not
recommended.
In several comparative trials in the treatment of
GERD, Cisapride appeared to show similar
efficacy to metoclopramide and comparable
efficacy and side effects to H2 Receptor
Antagonists.

Cisapride is initiated in adults at lOmg four times
daily given at least 15 minutes before meals and
at bedtime. Some patients may require 20mg
QID to obtain satisfactory results. The most
common adverse effects include dizziness,
vomiting, chest pain, fatigue, pharyngitis, back
pain, depression, dehydration, and myalgia.
Gastrointestinal side effects occur more frequently
at the 20mg dose vs the lOmg dose. Cisapride
has fewer CNS side effects than metoclopramide
(as well as no antiemetic effect). Cisapride was
added to the formulary for patients who are
unable to tolerate, or who are at greater risk for,
the extrapyramidal side effects associated with
metoclopramide therapy. Cisapride costs
$2.00/patient day (lOmg QID) vs $0.04/patient
day (lOmg QID) for metoclopramide. Cisapride
could affect the rate of absorption of other agents,
due to increased gastric emptying. Patients
receiving agents with narrow therapeutic indices
should be monitored closely. Coagulation times
have been increased in patients on oral anticoagulant therapy, therefore INR and/or PT's
should be done one week after the start and
discontinuation of cisapride.
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SAY NO TO CIPRO (Eye Drops, that is)
Ciprofloxacin Ophthalmic Solution (Ciloxan, Alcon)- is a topical antimicrobial agent indicated to treat
conjunctivitis and corneal ulceration caused by susceptible organisms. Ciprofloxacin was rejected due to
other formulary agents which adequately cover the most commonly seen pathogens. See Table 3.
TABLE 3: Spectrum of Antimicrobial Activity for Formulary Ophthalmic Agents and Ciprofloxacin
Bacitracin
$
GRAM-POSITIVE
Strep. pneumoniae
Staph. aureus(MSSA)
Staph. epidermidis
Beta-hemolytic strep
GRAM-t:!:EGATIVE
N.gonorrhoea
N.menigitidis
M.catarrhalis
H.influenzae
E. coli
Klebsiella sp.
Enterobacter sp.
Serratia sp.
Ps.aeruginosa
MISC
Chlamydia sp.

+
+
+
+
+
+

Ciprofloxacin
$$$

Gentamicin
$

±

+
+

+
+
+
+
+
+
+
+
+

±
±

0

±

NeosporinR
$

+
+
+

0

+
+
+
+
+
+

+
+
+
+
+

PolytrimR
$$$

Tobramycin
$$

±
±

+
+

±

+

0
0
0

0

0

0

+
+
+
+

+
+
+
+
+
+

+

Chloramphenicol
$$

+
+
+
+
+
+

+

1. McDonnell PJ. and WR Green. Eye Infections. In Mandell GL, ed. Principles and Practice of Infectious Diseases. 3rd ed. New

York; Churchill Livingstone; 1990.
2. Sanford JP. Guide to Antimicrobial Therapy: 1993.
3. Facts and Comparisons. St. Louis: 1993.

Pancrelipase (Pancrease MT, J & J) - is a micro
tablet formulation of digestive enzymes and is
indicated for patients with exocrine pancreatic
deficiency, i.e. cystic fibrosis, chronic
pancreatitis, etc. The MT formulation comes in 4
strengths with the number, following the "MT",
indicating the amount of lipase activity per
capsule. The MT formulation allows for dosage
adjustment while maintaining the same number of
capsules per dose. Pancrelipase is given with
meals and snacks and the dose should be adjusted
according

to patient response. Common adverse reactions
are generally gastrointestinal, with nausea,
abdominal cramping and diarrhea being most
common. Pancrease MT is indicated in children
over 1 year and adults. Because of the
formulation, Pancrease MT should not be
crushed. For patients unable to swallow the
capsules whole, the capsules may be opened,
sprinkled on soft food which doesn't require
chewing and taken immediately. Prolonged
contact with foods with pH greater than 6 can
dissolve the coating.
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DRUG USE EVALUATION CORNER
Ceftazidime - 66 patients on ceftazidime were

reviewed in August (increased from 54 in July).
54 (81. 8%) received ceftazidime empirically with
an average length of therapy of 3. 7 days. 3
(4. 5%) received on call doses for surgical bum
debridement. Ceftazidime to piperacillin chart
memos were placed on 7 char-..s with 2 changed to
piperacillin within 2 days, 3 with antibiotic
therapy D/C'd, and 2 changed to cefazolin. The
total number of patients treated with piperacillin
in August was 69 (decreased from 91 courses in
July).

)

Piperacilin is the preferred agent for aerobic gram
negative bacilli resistant to Cefazolin, in nonpenicillin allergic patients. For suspected
Pseudomonal infections, Piperacillin 5Gm Q8H is
recommended.

IV Ciprofloxacin- 33 patients receiving IV

ciprofloxacin were reviewed in August (increased
from 29 in July). 20 (64.5%) of the ciprofloxacin
use was empiric in patients with either a penicillin
allergy or recent failure to piperacillin or
ceftazidime. The average length of empiric
therapy was 3.6 days. 3 (9.7%) UTI's were
treated for an average of 1. 7 days. 8 patients
applicable for oral therapy had PO chart memos
placed with 5 changed to PO on day 2-5.
1 patient continued on IV therapy and 2 patients
had antibiotic therapy D/C'd.
Ciprofloxacin should be reserved for aerobic gram
negative bacilli (i.e. Pseudomonas, Enterobacter,
Serratia) resistant to standard therapy. With a

working GI tract, the oral formulation is equally
bioavailable at 116 the cost ($8.00/day vs
$50.00/day for 750mg PO and 400mg IV BID,
respectively).

Ampicillin!Sulbactam - Due to increasing

usage at LVH, ampicillin/SB was chosen for
monthly review. 63 patients receiving
ampicillin/SB were reviewed in August only.
13 (20.6%) fell into the mixed infection category.
One single pathogen infection (enterococcal
bacteremia) was also included in this group.
43 (68.3%) were treated empirically with an
average length of therapy of 3. 9 days. 7 ( 11.1 %)
cases of surgical prophylaxis utilized
ampicillin/SB x 12-72 hours.
Ampicillin/Sulbactam is best used in mixed
infections with S. Aureus or Enterococcus and
difficult anaerobic bacteria i.e. Bacteroides
species.
The Committee questioned how the data can be
better utilized to effect prescribing changes. The
Committee suggested that the Clinical Pharmacists
begin making suggestions to Prescribers who
appear to overprescribe broad spectrum and/ or
expensive agents when a more focused therapy
would be indicated based on culture and
suspectibility results and the clinical situation.
It was also noted that further cost awareness
efforts will be made by adding a cost scale
(multiple $ signs) to the Computer Susceptibility
screens together with the addition of cost data to
the actual antibiotic order sheet.

Page 25

KCL MINI-INFUSIONS
The Committee expanded the standardization of
diluents for Potassium Chloride mini-infusions by
accepting the recommendation that all "bolus
doses" will be given in sterile water as opposed to
custom dilutions. This change will further reduce
the amount of KCl vials on patient care areas and
the potential for serious medication errors through ·

misadministration. Dilution in sterile water also
offers the advantage of providing the dose with
the lowest osmolarity which lessens the potential
for venous irritation. Prior to this change, KCI
orders in DSW were substituted. Orders in NSS
are now included. To get a diluent other than
water, the Committee agreed that the Prescriber
must state that the diluent is medically necessary.

RESPIRATORY CARE POLICY REVISION
The Committee approved revisions to the
Respiratory Care Policy on Medications for
Bronchodilator Therapy. The revised policy
states that, if indications are not met on
assessment, therapy will not be given and the
Physician (or office staff) notified. In

addition, a sticker (See Table 4) will be
placed in the Progress Notes. Approximately
20% of nebulized bronchodilator therapy does
not meet indications. Physicians must write a
specific order to override this action.

TABLE 4: Respiratory Care Evaluation for Approved Medication Protocol
RESPIRATORY CARE EVALUATION FOR
APPROVED MEDICATION PROTOCOL
Bronchodilator Standards

DATE:
ORDER:
RX:
OX:
Progress notes reviewed Y N
Consults reviewed
y N
Nursing admission assessment
reviewed
y N

y
l.Asthma/reactive airways disease
N
2.COPO-Bronchitis & Emphysema
y
N
3.Bronchiectasis
y
N
4.Wheeze unchanged by cough
y
N
S.Improved spirometry or Raw on Vent
y
N
6.Cystic Fibrosis
y
N
7.Inhalation Burn/chemical trauma
y
N
B.Inspissated Secretions (Mucomyst)
y
N
9.For scutum induction
y
N
At this time your patient does not meet the above standards.
Resp RX has been 0/C'd
ORDERING PHYSIC!~~:
R.C.P:
Physician office notified of 0/C less than 24 Hrs. of init-ial order.
Notified: Date:
Time:

Patient Evaluation Sticker which will be placed
in the Progress Notes.
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